The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors.
Primary objectives:
To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I)
To characterize the safety and tolerability of IMA402 (Phase I/II)
To evaluate anti-tumor activity of IMA402 (Phase II)
Secondary objectives:
To evaluate the initial anti-tumor activity of IMA402 (Phase I)
To evaluate anti-tumor activity of IMA402 (Phase II)
To describe the PK of IMA402 (Phase I/II)
The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors.
Primary objectives:
To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I)
To characterize the safety and tolerability of IMA402 (Phase I/II)
To evaluate anti-tumor activity of IMA402 (Phase II)
Secondary objectives:
To evaluate the initial anti-tumor activity of IMA402 (Phase I)
To evaluate anti-tumor activity of IMA402 (Phase II)
To describe the PK of IMA402 (Phase I/II)
